On September 15, Oscar Health, Inc. rose 5.07% in regular trading, trading at $34.43 per share, with turnover of $108 million.

On the catalyst front, Bank of America recently raised its price target on the stock from $25 to $28, with the average analyst consensus target standing at $31.09. The upward revision follows a blowout Q2 earnings report, in which the company posted EPS of $1.10, more than doubling the consensus estimate of approximately $0.42. Revenue reached $4.88 billion, beating the $4.75 billion estimate and surging over 70% year-over-year. Total effectuated membership climbed 46% year-over-year to approximately 2.96 million. The company reaffirmed full-year revenue guidance of $18.7 billion to $19.0 billion, above consensus. Multiple firms have raised targets in recent months, including Barclays upgrading to Overweight with a $35 target and UBS lifting its target from $20 to $26.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)